Autoimmune AQP4 channelopathies and neuromyelitis optica spectrum disorders

Shannon R. Hinson, Vanda A Lennon, Sean J Pittock

Research output: Chapter in Book/Report/Conference proceedingConference contribution

22 Citations (Scopus)

Abstract

Neuromyelitis optica (NMO) spectrum disorders (SD) represent an evolving group of central nervous system (CNS)-inflammatory autoimmune demyelinating diseases unified by a pathogenic autoantibody specific for the aquaporin-4 (AQP4) water channel. It was historically misdiagnosed as multiple sclerosis (MS), which lacks a distinguishing biomarker. The discovery of AQP4-IgG moved the focus of CNS demyelinating disease research from emphasis on the oligodendrocyte and myelin to the astrocyte. NMO is recognized today as a relapsing disease, extending beyond the optic nerves and spinal cord to include brain (especially in children) and skeletal muscle. Brain magnetic resonance imaging abnormalities, identifiable in 60% of patients at the second attack, are consistent with MS in 10% of cases. NMOSD-typical lesions (another 10%) occur in AQP4-enriched regions: circumventricular organs (causing intractable nausea and vomiting) and the diencephalon (causing sleep disorders, endocrinopathies, and syndrome of inappropriate antidiuresis). Advances in understanding the immunobiology of AQP4 autoimmunity have necessitated continuing revision of NMOSD clinical diagnostic criteria. Assays that selectively detect pathogenic AQP4-IgG targeting extracellular epitopes of AQP4 are promising prognostically. When referring to AQP4 autoimmunity, we suggest substituting the term "autoimmune aquaporin-4 channelopathy" for the term "NMO spectrum disorders." Randomized clinical trials are currently assessing the efficacy and safety of newer immunotherapies. Increasing therapeutic options based on understanding the molecular pathogenesis is anticipated to improve the outcome for patients with AQP4 channelopathy.

Original languageEnglish (US)
Title of host publicationAutoimmune Neurology, 2016
PublisherElsevier
Pages377-403
Number of pages27
Volume133
ISBN (Print)9780444634320
DOIs
StatePublished - 2016

Publication series

NameHandbook of Clinical Neurology
Volume133
ISSN (Print)00729752
ISSN (Electronic)22124152

Fingerprint

Channelopathies
Aquaporin 4
Neuromyelitis Optica
Autoimmunity
Multiple Sclerosis
CNS Demyelinating Autoimmune Diseases
Immunoglobulin G
Diencephalon
Aquaporins
Central Nervous System Diseases
Oligodendroglia
Brain
Demyelinating Diseases
Optic Nerve
Myelin Sheath
Diagnostic Errors
Astrocytes
Autoantibodies
Immunotherapy
Nausea

Keywords

  • AQP4
  • Astrocyle
  • Demyelination
  • EAAT2
  • Multiple sclerosis
  • Neuromyelitis optica
  • Optic neuritis
  • Transverse myelitis
  • Water channel

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

Hinson, S. R., Lennon, V. A., & Pittock, S. J. (2016). Autoimmune AQP4 channelopathies and neuromyelitis optica spectrum disorders. In Autoimmune Neurology, 2016 (Vol. 133, pp. 377-403). (Handbook of Clinical Neurology; Vol. 133). Elsevier. https://doi.org/10.1016/B978-0-444-63432-0.00021-9

Autoimmune AQP4 channelopathies and neuromyelitis optica spectrum disorders. / Hinson, Shannon R.; Lennon, Vanda A; Pittock, Sean J.

Autoimmune Neurology, 2016. Vol. 133 Elsevier, 2016. p. 377-403 (Handbook of Clinical Neurology; Vol. 133).

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Hinson, SR, Lennon, VA & Pittock, SJ 2016, Autoimmune AQP4 channelopathies and neuromyelitis optica spectrum disorders. in Autoimmune Neurology, 2016. vol. 133, Handbook of Clinical Neurology, vol. 133, Elsevier, pp. 377-403. https://doi.org/10.1016/B978-0-444-63432-0.00021-9
Hinson SR, Lennon VA, Pittock SJ. Autoimmune AQP4 channelopathies and neuromyelitis optica spectrum disorders. In Autoimmune Neurology, 2016. Vol. 133. Elsevier. 2016. p. 377-403. (Handbook of Clinical Neurology). https://doi.org/10.1016/B978-0-444-63432-0.00021-9
Hinson, Shannon R. ; Lennon, Vanda A ; Pittock, Sean J. / Autoimmune AQP4 channelopathies and neuromyelitis optica spectrum disorders. Autoimmune Neurology, 2016. Vol. 133 Elsevier, 2016. pp. 377-403 (Handbook of Clinical Neurology).
@inproceedings{31b370d5788e4ebf87294d00ee992d22,
title = "Autoimmune AQP4 channelopathies and neuromyelitis optica spectrum disorders",
abstract = "Neuromyelitis optica (NMO) spectrum disorders (SD) represent an evolving group of central nervous system (CNS)-inflammatory autoimmune demyelinating diseases unified by a pathogenic autoantibody specific for the aquaporin-4 (AQP4) water channel. It was historically misdiagnosed as multiple sclerosis (MS), which lacks a distinguishing biomarker. The discovery of AQP4-IgG moved the focus of CNS demyelinating disease research from emphasis on the oligodendrocyte and myelin to the astrocyte. NMO is recognized today as a relapsing disease, extending beyond the optic nerves and spinal cord to include brain (especially in children) and skeletal muscle. Brain magnetic resonance imaging abnormalities, identifiable in 60{\%} of patients at the second attack, are consistent with MS in 10{\%} of cases. NMOSD-typical lesions (another 10{\%}) occur in AQP4-enriched regions: circumventricular organs (causing intractable nausea and vomiting) and the diencephalon (causing sleep disorders, endocrinopathies, and syndrome of inappropriate antidiuresis). Advances in understanding the immunobiology of AQP4 autoimmunity have necessitated continuing revision of NMOSD clinical diagnostic criteria. Assays that selectively detect pathogenic AQP4-IgG targeting extracellular epitopes of AQP4 are promising prognostically. When referring to AQP4 autoimmunity, we suggest substituting the term {"}autoimmune aquaporin-4 channelopathy{"} for the term {"}NMO spectrum disorders.{"} Randomized clinical trials are currently assessing the efficacy and safety of newer immunotherapies. Increasing therapeutic options based on understanding the molecular pathogenesis is anticipated to improve the outcome for patients with AQP4 channelopathy.",
keywords = "AQP4, Astrocyle, Demyelination, EAAT2, Multiple sclerosis, Neuromyelitis optica, Optic neuritis, Transverse myelitis, Water channel",
author = "Hinson, {Shannon R.} and Lennon, {Vanda A} and Pittock, {Sean J}",
year = "2016",
doi = "10.1016/B978-0-444-63432-0.00021-9",
language = "English (US)",
isbn = "9780444634320",
volume = "133",
series = "Handbook of Clinical Neurology",
publisher = "Elsevier",
pages = "377--403",
booktitle = "Autoimmune Neurology, 2016",

}

TY - GEN

T1 - Autoimmune AQP4 channelopathies and neuromyelitis optica spectrum disorders

AU - Hinson, Shannon R.

AU - Lennon, Vanda A

AU - Pittock, Sean J

PY - 2016

Y1 - 2016

N2 - Neuromyelitis optica (NMO) spectrum disorders (SD) represent an evolving group of central nervous system (CNS)-inflammatory autoimmune demyelinating diseases unified by a pathogenic autoantibody specific for the aquaporin-4 (AQP4) water channel. It was historically misdiagnosed as multiple sclerosis (MS), which lacks a distinguishing biomarker. The discovery of AQP4-IgG moved the focus of CNS demyelinating disease research from emphasis on the oligodendrocyte and myelin to the astrocyte. NMO is recognized today as a relapsing disease, extending beyond the optic nerves and spinal cord to include brain (especially in children) and skeletal muscle. Brain magnetic resonance imaging abnormalities, identifiable in 60% of patients at the second attack, are consistent with MS in 10% of cases. NMOSD-typical lesions (another 10%) occur in AQP4-enriched regions: circumventricular organs (causing intractable nausea and vomiting) and the diencephalon (causing sleep disorders, endocrinopathies, and syndrome of inappropriate antidiuresis). Advances in understanding the immunobiology of AQP4 autoimmunity have necessitated continuing revision of NMOSD clinical diagnostic criteria. Assays that selectively detect pathogenic AQP4-IgG targeting extracellular epitopes of AQP4 are promising prognostically. When referring to AQP4 autoimmunity, we suggest substituting the term "autoimmune aquaporin-4 channelopathy" for the term "NMO spectrum disorders." Randomized clinical trials are currently assessing the efficacy and safety of newer immunotherapies. Increasing therapeutic options based on understanding the molecular pathogenesis is anticipated to improve the outcome for patients with AQP4 channelopathy.

AB - Neuromyelitis optica (NMO) spectrum disorders (SD) represent an evolving group of central nervous system (CNS)-inflammatory autoimmune demyelinating diseases unified by a pathogenic autoantibody specific for the aquaporin-4 (AQP4) water channel. It was historically misdiagnosed as multiple sclerosis (MS), which lacks a distinguishing biomarker. The discovery of AQP4-IgG moved the focus of CNS demyelinating disease research from emphasis on the oligodendrocyte and myelin to the astrocyte. NMO is recognized today as a relapsing disease, extending beyond the optic nerves and spinal cord to include brain (especially in children) and skeletal muscle. Brain magnetic resonance imaging abnormalities, identifiable in 60% of patients at the second attack, are consistent with MS in 10% of cases. NMOSD-typical lesions (another 10%) occur in AQP4-enriched regions: circumventricular organs (causing intractable nausea and vomiting) and the diencephalon (causing sleep disorders, endocrinopathies, and syndrome of inappropriate antidiuresis). Advances in understanding the immunobiology of AQP4 autoimmunity have necessitated continuing revision of NMOSD clinical diagnostic criteria. Assays that selectively detect pathogenic AQP4-IgG targeting extracellular epitopes of AQP4 are promising prognostically. When referring to AQP4 autoimmunity, we suggest substituting the term "autoimmune aquaporin-4 channelopathy" for the term "NMO spectrum disorders." Randomized clinical trials are currently assessing the efficacy and safety of newer immunotherapies. Increasing therapeutic options based on understanding the molecular pathogenesis is anticipated to improve the outcome for patients with AQP4 channelopathy.

KW - AQP4

KW - Astrocyle

KW - Demyelination

KW - EAAT2

KW - Multiple sclerosis

KW - Neuromyelitis optica

KW - Optic neuritis

KW - Transverse myelitis

KW - Water channel

UR - http://www.scopus.com/inward/record.url?scp=84978370276&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84978370276&partnerID=8YFLogxK

U2 - 10.1016/B978-0-444-63432-0.00021-9

DO - 10.1016/B978-0-444-63432-0.00021-9

M3 - Conference contribution

C2 - 27112688

AN - SCOPUS:84978370276

SN - 9780444634320

VL - 133

T3 - Handbook of Clinical Neurology

SP - 377

EP - 403

BT - Autoimmune Neurology, 2016

PB - Elsevier

ER -